Head to Head Survey: Ampio Pharmaceuticals (NYSE:AMPE) vs. Palatin Technologies (OTCMKTS:PTNT)

Volatility & Risk

Ampio Pharmaceuticals has a beta of 7.65, meaning that its share price is 665% more volatile than the S&P 500. Comparatively, Palatin Technologies has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Ampio Pharmaceuticals and Palatin Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Palatin Technologies	N/A	N/A	-365.57%

Insider & Institutional Ownership

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.5% of Palatin Technologies shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Palatin Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Ampio Pharmaceuticals and Palatin Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	0.00
Palatin Technologies	$4.49 million	49.41	-$29.74 million	($1.55)	-5.50

Ampio Pharmaceuticals has higher earnings, but lower revenue than Palatin Technologies. Palatin Technologies is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.